论文部分内容阅读
目的 :对目前临床治疗非小细胞肺癌的MVP ,NP ,TI 3种化疗方案的疗效、毒性和费用进行评价分析。方法 :用药物经济学中的成本指标、成本效果分析和敏感度分析 3项指标对化疗方案进行评价。结果 :以费用指标比较 ,MVP方案的成本指标和成本效果分析两项考察指标均优于NP和TI方案。进行敏感度分析 ,用西药费和总花费代替化疗费作为费用指标进行分析 ,NP方案与MVP方案成本效果比基本持平 ,优于TI方案。结论 :由于NP方案与MVP方案成本效果比无显著差异 ,应选择疗效更好的方案 ,即NP方案。
OBJECTIVE: To evaluate and evaluate the efficacy, toxicity and cost of three chemotherapy regimens of MVP, NP and TI in clinical treatment of non-small cell lung cancer. Methods: Three indicators of cost index, cost-effectiveness analysis and sensitivity analysis in pharmacoeconomics were used to evaluate the chemotherapy regimen. Results: Compared with the cost index, the cost index and the cost-effectiveness analysis of the MVP scheme were better than the NP and TI schemes. Sensitivity analysis, Western medicine costs and total costs instead of chemotherapy costs as an indicator of cost analysis, NP program and MVP program cost-effective than the basic, better than the TI program. Conclusion: Because the cost-effectiveness of NP and MVP schemes is not significantly different, we should choose a more effective scheme, NP scheme.